American Century Companies Inc. Boosts Stock Position in AbbVie Inc. $ABBV

American Century Companies Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 11.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,428,814 shares of the company’s stock after buying an additional 349,973 shares during the period. AbbVie comprises about 0.3% of American Century Companies Inc.’s holdings, making the stock its 28th biggest position. American Century Companies Inc. owned about 0.19% of AbbVie worth $636,457,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the 2nd quarter worth about $25,000. TD Capital Management LLC increased its stake in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the second quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. lifted its stake in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 2.9%

Shares of NYSE ABBV opened at $236.12 on Friday. The stock has a market capitalization of $417.31 billion, a P/E ratio of 112.44, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The firm’s 50 day simple moving average is $226.81 and its two-hundred day simple moving average is $205.35. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the business posted $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 2.9%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Wells Fargo & Company boosted their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Daiwa Capital Markets upgraded AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a research report on Thursday, August 7th. Finally, Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.